Winald R. Gerritsen
Hoofddorp, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 134 publications
[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study.
Journal: The Lancet. Oncology
Published: August 12, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 05, 2025
Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with 223Ra Therapy in Daily Practice.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 05, 2025
Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.
Journal: European urology oncology
Published: January 03, 2025
Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Journal: Clinical genitourinary cancer
Published: December 03, 2024
Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-study.
Journal: British journal of cancer
Published: December 03, 2024
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 13, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.
Journal: Prostate cancer and prostatic diseases
Published: February 28, 2024
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
Journal: European urology
Published: December 21, 2023
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 10, 2023
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
Journal: Nature communications
Published: May 09, 2023
Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
Journal: European urology oncology
Published: April 13, 2023
Last Updated: 09/26/2026